Monte Rosa Therapeutics, Inc. (GLUE) announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6.
"In this interim data readout, after 4 weeks of dosing MRT-8102 decreased median high-sensitivity CRP levels by 85% and resulted in suppression of hsCRP to <2 mg/L in 94% of subjects, despite a significantly higher median baseline level of 6.3 mg/L as compared to benchmark clinical trials," said Markus Warmuth, CEO of Monte Rosa Therapeutics.
In pre-market trading on NasdaqGS, Monte Rosa shares are up 42.6 percent to $22.83.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.